Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|September 1, 2021
SK Bioscience and GSK Start Phase III Trial of Adjuvanted COVID-19 Vaccine Candidate
Author(s)Pharmaceutical Technology Editors
SK and GSK announce the initiation of a Phase III clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant.
Advertisement
SK bioscience (SK) and GlaxoSmithKline (GSK) announced the initiation of a Phase III clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results in an Aug. 31, 2021 press release. The Phase III clinical study is a randomized, active-controlled global trial that will enroll approximately 4,000 participants. It will evaluate GBP510’s safety and immunogenicity compared to the AstraZeneca/Oxford University COVID-19 vaccine. This will be one of the first global Phase III trials to compare two different COVID-19 vaccine candidates.
Interim Phase I/II data showed that participants who received the adjuvanted vaccine candidate developed strong neutralizing antibody responses, demonstrating a 100% seroconversion rate. No safety concerns have been identified to date in the ongoing study.
Results from the Phase III study are expected in the first half of 2022. The vaccine is then expected to be supplied worldwide through the COVAX facility, pending positive results and regulatory approval.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement